Amian A, Rodríguez J N, Diéguez J C, Cañavate M, Fernández A, Martino M L, Muñiz R, Prados D
Servicio de Hematología y Hemoterapia, Hospital General de Huelva.
Sangre (Barc). 1993 Oct;38(5):349-53.
We have studied the haemorrhagic episodes occurred in patients treated with oral anticoagulants, with special reference to their type, frequency and severity and analyzing the risk factors that could influence in their production.
We carried out a retrospective study in 435 patients of the haemorrhagic episodes occurred since January 1989 to December 1991, determining in each one the prothrombin time expressed as INR, the time from the beginning of treatment, the patient's age and the known or underlying pathologies that could predispose to haemorrhage; depending on their severity these episodes were classified as moderate and major.
We observed 50 haemorrhagic episodes in 50 patients (11.5%) which represents 7 x 100 patient/years, 30 (6.8% of the total patients or 4.2 x 100 patient-years) were moderate and 20 (4.5% of the total patients or 2.8 x 100 patient/years) were major. The mean age in patients with haemorrhage was 50.5 years. The incidence of hemorrhages in the first month of treatment was 60.8 x 100 patient/years; 9.4 x 100 patient/years in the period from the first month to the first year of treatment; and 3.6 x 100 patient/years in the period from the first year of treatment. The most frequent type of haemorrhage among the moderate ones was haematuria (46%) and among major ones digestive haemorrhages (26%). Depending on the coagulation level, 37 patients (66%) were within therapeutical range. Depending on patients' sex, the incidence was 23 (46%) males and 27 (54%) females. We observed at risk predisposing factors hypertension (18%), stroke (12%), hepatic disease (8%) and myocardial infarction (8%).
We have found no relationship between haemorrhagic episodes and patients' age or sex. The risk of haemorrhage is higher at the beginning of the treatment and increases with the level of anticoagulation, which makes the beginning of treatment with lower doses more desirable, increasing them progressively until the desired level is achieved. Previous hypertension, stroke, hepatic disease and myocardial infarction are factors predisposing to haemorrhage.
我们研究了接受口服抗凝剂治疗的患者发生的出血事件,特别关注其类型、频率和严重程度,并分析了可能影响其发生的危险因素。
我们对1989年1月至1991年12月期间发生出血事件的435例患者进行了回顾性研究,测定了每例患者以国际标准化比值(INR)表示的凝血酶原时间、治疗开始后的时间、患者年龄以及可能易导致出血的已知或潜在疾病;根据严重程度,这些事件分为中度和重度。
我们在50例患者(11.5%)中观察到50次出血事件,相当于7×100患者/年,30次(占总患者的6.8%或4.2×100患者-年)为中度,20次(占总患者的4.5%或2.8×100患者/年)为重度。出血患者的平均年龄为50.5岁。治疗第一个月的出血发生率为60.8×100患者/年;治疗第一个月至第一年期间为9.4×100患者/年;治疗第一年以后为3.6×100患者/年。中度出血中最常见的类型是血尿(46%),重度出血中最常见的是消化道出血(26%)。根据凝血水平,37例患者(66%)处于治疗范围内。根据患者性别,发生率为男性23例(46%),女性27例(54%)。我们观察到的易患危险因素有高血压(18%)、中风(12%)、肝病(8%)和心肌梗死(8%)。
我们发现出血事件与患者年龄或性别之间没有关系。治疗开始时出血风险较高,且随着抗凝水平的升高而增加,这使得开始用较低剂量治疗更可取,逐渐增加剂量直至达到所需水平。既往高血压、中风、肝病和心肌梗死是易导致出血的因素。